About

​

Jamie Triccas is Professor of Medical Microbiology and Deputy Director of the Sydney Institute Infectious Diseases (Sydney ID) at the University of Sydney. His group uses a multidisciplinary approach to define immunity to chronic bacterial pathogens and develop new treatments to control infection. He leads the University of Sydney, ExcellGene and Bharat Biotech consortium, supported by the Coalition for Epidemic Preparedness Innovations (CEPI), to develop a broadly protective SARS-CoV-2 vaccine. He is Principal Investigator on the NIH Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) contract, a 5-year program to identify adjuvant-TB immunogen candidates for clinical development and define immune correlates of protection

​

Academic Profile